DOP2011000166A - Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico - Google Patents

Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico

Info

Publication number: DOP2011000166A
Authority: DO; Dominican Republic
Prior art keywords: preparation; tetrahidropiran; pirrolidinona; piperidinona; espiro
Prior art date: 2008-12-05

Application number

DO2011000166A

Other languages

English (en)

Spanish (es)

Inventor

David Stefany

Zhongli Gao

Ryan Hartung

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-05

Filing date

2011-06-01

Publication date

2011-10-31

2011-06-01 Application filed by Sanofi Sa filed Critical Sanofi Sa

2011-10-31 Publication of DOP2011000166A publication Critical patent/DOP2011000166A/es

Links

230000001225 therapeutic effect Effects 0.000 title 1
102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
KFIOZBMCNUODPK-UHFFFAOYSA-N n-phenyl-1-pyrrolidin-1-ylpyrrolidine-2-carboxamide Chemical class C1CCN(N2CCCC2)C1C(=O)NC1=CC=CC=C1 KFIOZBMCNUODPK-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

DO2011000166A 2008-12-05 2011-06-01 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico DOP2011000166A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12008708P	2008-12-05	2008-12-05
FR0955909		2009-08-28

Publications (1)

Publication Number	Publication Date
DOP2011000166A true DOP2011000166A (es)	2011-10-31

Family

ID=41665099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DO2011000166A DOP2011000166A (es)	2008-12-05	2011-06-01	Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico

Country Status (27)

Country	Link
US (2)	US8217052B2 (fr)
EP (1)	EP2373659B1 (fr)
JP (1)	JP5410544B2 (fr)
KR (1)	KR101682889B1 (fr)
CN (1)	CN102239170B (fr)
AR (1)	AR074467A1 (fr)
AU (1)	AU2009322243B2 (fr)
CA (1)	CA2745715C (fr)
CO (1)	CO6390059A2 (fr)
CR (1)	CR20110289A (fr)
DO (1)	DOP2011000166A (fr)
EC (1)	ECSP11011109A (fr)
ES (1)	ES2507574T3 (fr)
HN (1)	HN2011001487A (fr)
IL (1)	IL213292A (fr)
MA (1)	MA32945B1 (fr)
MX (1)	MX2011004791A (fr)
MY (1)	MY150789A (fr)
NZ (1)	NZ593150A (fr)
PA (1)	PA8852301A1 (fr)
PE (1)	PE20110773A1 (fr)
RU (1)	RU2519778C2 (fr)
TN (1)	TN2011000223A1 (fr)
TW (1)	TWI441826B (fr)
UA (1)	UA104880C2 (fr)
WO (1)	WO2010065798A1 (fr)
ZA (1)	ZA201103261B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR074466A1 (es)	2008-12-05	2011-01-19	Sanofi Aventis	Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
EP2569297A1 (fr)	2010-05-11	2013-03-20	Sanofi	Dérivés de n-hétérocycloalkyl-bipyrrolidinylphénylamide substitués, préparation et utilisation thérapeutique de ceux-ci
WO2011143162A1 (fr)	2010-05-11	2011-11-17	Sanofi	Carboxamides de n-hétéroaryl-bipyrrolidine substitués, leur préparation et leur utilisation thérapeutique
AR083718A1 (es)	2010-05-11	2013-03-20	Sanofi Aventis	Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
WO2011143155A1 (fr)	2010-05-11	2011-11-17	Sanofi	Dérivés de n-hétéroaryl tétrahydro-isoquinolines substituées, procédé de préparation et usage thérapeutique associés
JP5833105B2 (ja)	2010-05-11	2015-12-16	サノフイ	置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
TW201206889A (en)	2010-05-11	2012-02-16	Sanofi Aventis	Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
TW201206898A (en) *	2010-05-11	2012-02-16	Sanofi Aventis	Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3256276A (en) *	1961-02-17	1966-06-14	Geschickter Fund Med Res	Substituted spiroimides
US3258276A (en)	1964-04-06	1966-06-28	Charles E Murcott	Utility chair
EP2243776A1 (fr) *	2001-10-12	2010-10-27	High Point Pharmaceuticals, LLC	Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3
US6889262B1 (en)	2002-06-26	2005-05-03	Advanced Micro Devices, Inc.	Direct transaction mode for peripheral devices
US7279491B2 (en) *	2002-10-23	2007-10-09	Janssen Pharmaceutica N.V.	Phenylpiperidines and phenylpyrrolidines
US7223788B2 (en)	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
AU2004274309B2 (en) *	2003-09-22	2010-04-08	Msd K.K.	Novel piperidine derivative
EP1904442B1 (fr) *	2005-07-01	2011-09-07	Eli Lilly And Company	Agents recepteurs de l'histamine h3, preparation et utilisations therapeutiques
US8158791B2 (en) *	2005-11-10	2012-04-17	Msd K.K.	Aza-substituted spiro derivatives
BRPI0619985A2 (pt)	2005-12-16	2011-10-25	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
US20080247964A1 (en) *	2006-05-08	2008-10-09	Yuelian Xu	Substituted azaspiro derivatives
US8318927B2 (en) *	2006-05-23	2012-11-27	High Point Pharmaceuticals, Llc	6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
CA2656089A1 (fr)	2006-06-29	2008-01-03	Janssen Pharmaceutica N.V.	Composes de benzylamine substituee
US20100317679A1 (en)	2007-09-21	2010-12-16	Ligand Pharmaceuticals, Inc.	Substituted aryl-fused spirocyclic amines
CN101903340B (zh)	2007-10-17	2013-03-27	赛诺菲-安万特	取代的n-苯基联吡咯烷羧酰胺及其治疗用途
EP2212282B1 (fr)	2007-10-17	2011-09-21	Sanofi	Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique
CN101903342B (zh)	2007-10-17	2012-11-21	赛诺菲-安万特	取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途
AR074466A1 (es)	2008-12-05	2011-01-19	Sanofi Aventis	Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

2009
- 2009-12-03 AR ARP090104667A patent/AR074467A1/es unknown
- 2009-12-04 TW TW098141444A patent/TWI441826B/zh not_active IP Right Cessation
- 2009-12-04 MY MYPI20112068 patent/MY150789A/en unknown
- 2009-12-04 WO PCT/US2009/066666 patent/WO2010065798A1/fr not_active Ceased
- 2009-12-04 MX MX2011004791A patent/MX2011004791A/es active IP Right Grant
- 2009-12-04 JP JP2011539715A patent/JP5410544B2/ja active Active
- 2009-12-04 CA CA2745715A patent/CA2745715C/fr not_active Expired - Fee Related
- 2009-12-04 RU RU2011127382/04A patent/RU2519778C2/ru not_active IP Right Cessation
- 2009-12-04 AU AU2009322243A patent/AU2009322243B2/en not_active Ceased
- 2009-12-04 CN CN200980148490.7A patent/CN102239170B/zh active Active
- 2009-12-04 ES ES09775421.2T patent/ES2507574T3/es active Active
- 2009-12-04 NZ NZ593150A patent/NZ593150A/xx not_active IP Right Cessation
- 2009-12-04 PA PA20098852301A patent/PA8852301A1/es unknown
- 2009-12-04 KR KR1020117014404A patent/KR101682889B1/ko not_active Expired - Fee Related
- 2009-12-04 UA UAA201108412A patent/UA104880C2/uk unknown
- 2009-12-04 EP EP09775421.2A patent/EP2373659B1/fr active Active
- 2009-12-04 MA MA33989A patent/MA32945B1/fr unknown
- 2009-12-04 PE PE2011001127A patent/PE20110773A1/es not_active Application Discontinuation
2011
- 2011-05-05 ZA ZA2011/03261A patent/ZA201103261B/en unknown
- 2011-05-06 TN TN2011000223A patent/TN2011000223A1/fr unknown
- 2011-05-27 CR CR20110289A patent/CR20110289A/es unknown
- 2011-05-31 IL IL213292A patent/IL213292A/en not_active IP Right Cessation
- 2011-06-01 DO DO2011000166A patent/DOP2011000166A/es unknown
- 2011-06-02 US US13/151,925 patent/US8217052B2/en active Active
- 2011-06-02 CO CO11068492A patent/CO6390059A2/es active IP Right Grant
- 2011-06-03 HN HN2011001487A patent/HN2011001487A/es unknown
- 2011-06-03 EC EC2011011109A patent/ECSP11011109A/es unknown
2012
- 2012-05-30 US US13/483,503 patent/US8383814B2/en active Active

Also Published As

Publication number	Publication date
MY150789A (en)	2014-02-28
TW201033219A (en)	2010-09-16
CR20110289A (es)	2011-09-21
AU2009322243B2 (en)	2015-07-16
US8383814B2 (en)	2013-02-26
HN2011001487A (es)	2013-12-02
TWI441826B (zh)	2014-06-21
JP5410544B2 (ja)	2014-02-05
IL213292A (en)	2014-01-30
RU2519778C2 (ru)	2014-06-20
CN102239170A (zh)	2011-11-09
IL213292A0 (en)	2011-07-31
EP2373659B1 (fr)	2014-07-30
CN102239170B (zh)	2014-08-20
ZA201103261B (en)	2012-01-25
CO6390059A2 (es)	2012-02-29
MX2011004791A (es)	2011-05-30
AR074467A1 (es)	2011-01-19
KR20110095911A (ko)	2011-08-25
ECSP11011109A (es)	2011-11-30
JP2012511011A (ja)	2012-05-17
TN2011000223A1 (en)	2012-12-17
NZ593150A (en)	2012-10-26
PE20110773A1 (es)	2011-10-26
AU2009322243A1 (en)	2011-06-23
KR101682889B1 (ko)	2016-12-06
WO2010065798A1 (fr)	2010-06-10
CA2745715C (fr)	2014-01-28
ES2507574T3 (es)	2014-10-15
PA8852301A1 (es)	2010-07-27
EP2373659A1 (fr)	2011-10-12
US20110251225A1 (en)	2011-10-13
UA104880C2 (uk)	2014-03-25
CA2745715A1 (fr)	2010-06-10
US8217052B2 (en)	2012-07-10
RU2011127382A (ru)	2013-01-10
MA32945B1 (fr)	2012-01-02
US20120238757A1 (en)	2012-09-20

Publication	Publication Date	Title
ECSP11011108A (es)	2011-11-30	Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
DOP2011000166A (es)	2011-10-31	Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico
CY1112083T1 (el)	2015-11-04	Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
CO6190616A2 (es)	2010-08-19	Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
CY1112391T1 (el)	2015-12-09	Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
UY30572A1 (es)	2008-05-02	N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR9734A (es)	2008-04-03	Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CR9733A (es)	2008-04-02	Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR10474A (es)	2009-01-07	Derivados de benzozazol y benzotiazol como ligandos de 5-hidroxitriptamina-6
UY32294A (es)	2010-07-30	Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
NI201100090A (es)	2011-11-03	Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico.
NI201100094A (es)	2011-11-03	Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico.
CR10339A (es)	2008-11-18	Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
UY30526A1 (es)	2008-03-31	Imidazolina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso